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In the present study, the recognition of epitope variants of influenza A viruses by human CTL was investigated. To this end, human
CD8 CTL clones, specific for natural variants of the HLA-B*3501-restricted epitope in the nucleoprotein (NP418–426), were
generated. As determined in 51Cr release assays and by flow cytometry with HLA-B*3501-peptide tetrameric complexes, CTL
clones were found to be specific for epitopes within one subtype or cross-reactive with heterosubtypic variants of the epitope. Using
eight natural variants of the epitope, positions in the 9-mer important for T cell recognition and involved in escape from CTL
immunity were identified and visualized using multidimensional scaling. It was shown that positions 4 and 5 in the 9-mer epitope
were important determinants of T cell specificity. The in vivo existence of CD8 cells cross-reactive with homo- and heterosubtypic
variants of the epitope was further confirmed using polyclonal T cell populations obtained after stimulation of PBMC with
different influenza A viruses. Based on the observed recognition patterns of the clonal and polyclonal T cell populations and
serology, it is hypothesized that consecutive infections with influenza viruses containing different variants of the epitope select for
cross-reactive T cells in vivo. The Journal of Immunology, 2004, 172: 2453–2460.
C ytotoxic T lymphocytes play an important role in thecontrol of viral infections. In influenza A virus-infectedmice, CTL were shown to contribute to protective im-
munity against viruses of various subtypes (1–5), while human
CTL have been reported to reduce morbidity and virus titers in the
lung (6, 7). Recently, it was demonstrated that CTL immunity can
exert selective pressure on influenza A virus CTL epitopes, further
implicating a role for CTL in the control of influenza virus repli-
cation in infected individuals (8, 9). Beside amino acid changes in
the anchor residues of CTL epitopes (8), changes in nonanchor
residues were observed in an HLA-B*3501-restricted CTL epitope
within the nucleoprotein (NP)3 of influenza A virus (NP418–426)
(9). Epitope variants of influenza A (H3N2) viruses (homosubtypic
variants) were found to emerge in a chronological order (9). In
addition, a variant of the epitope was identified in influenza A
(H1N1) viruses, which differed from those found in A/H3N2 vi-
ruses (heterosubtypic variant). Although the majority of CTL
epitopes are conserved between different subtypes (2, 10–13), both
human and murine CTL have been described that recognize a sin-
gle subtype of influenza A virus (9, 10, 14–16). It has been shown
that sequential infections with two influenza A viruses, containing
different variants of the same epitope, induced CTL reactive
against both epitopes, whereas infection with one influenza A virus
only induced CTL reactive with the homologous peptide sequence
(17, 18). These experiments were conducted in naive mice and are
difficult to extrapolate to humans. Data on the cross-reactive nature
of human influenza A virus-specific CTL are limited (19).
The observed variability in the HLA-B*3501-restricted epitope
NP418–426 allows investigation of the cross-reactive nature of CTL
obtained from humans which constitute a natural host for influenza
viruses. In this study, the recognition of natural epitope variants by
clonal and polyclonal T cell populations was studied. T cell rec-
ognition was studied in conventional 51Cr release assays and also
by direct visualization of T cells displaying monospecific or cross-
reactive TCRs using HLA-B*3501-peptide tetrameric complexes
(20).
It was found that most CTL recognize one subtype of currently
circulating influenza A viruses. However, some of the CTL exhib-
ited a broader recognition pattern and recognized homosubtypic
and even heterosubtypic variants of epitope NP418–426. Based on
these findings obtained in vitro, the origin of these cross-reactive
CTL is discussed.
Materials and Methods
Cells
PBMC from normal healthy nonvaccinated HLA-B35 blood donors (Ta-
ble I), between 30 and 48 years of age, were isolated between 1999 and
2001 using Lymphoprep (Nycomed, Oslo, Norway) gradient centrifugation
and cryopreserved at 135°C. HLA sero- and genotyping was performed
in the laboratory for Histocompatibility and Immunogenetics at the San-
quin Bloodbank Rotterdam (The Netherlands) using a commercial typing
system (GenoVision, Vienna, Austria).
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Serology
Plasma samples were stored at 20°C and tested for the presence of in-
fluenza A virus (H3N2 and H1N1)-specific Abs in a hemagglutination
inhibition (HAI) assay according to standard methods (21, 22) using turkey
erythrocytes and four hemagglutinating units of virus. The sera were tested
for Abs against 11 vaccine strains of subtype H3N2 and 6 vaccine strains
of the H1N1 subtype used since 1968. Ferret sera raised against the test
Ags were used as positive controls. A HAI titer of 20 against a vaccine
strain used in a particular season was considered indicative of an infection
with an epidemic influenza A virus of that year.
Influenza A viruses and peptides
Sucrose gradient purified influenza A viruses were used for the infection of
PBMC and cells of B lymphoblastoid cell lines (BLCL). Resvir-9 is a
reassortant virus between A/Puerto Rico/8/34 (H1N1) and A/Nanchang/
933/95 (H3N2) containing the NP, hemagglutinin, and neuraminidase of
A/Nanchang/933/95 with the LPFEKSTVM variant of the NP418–426
epitope (designated NPESV), which was first identified in 1980 (Table II).
A second virus, A/Victoria/3/75 (H3N2) containing the LPFDKSTIM vari-
ant of the NP418–426 epitope (designated NPDSI), introduced in 1972, was
also used. As prototype of currently circulating H1N1 viruses in The Neth-
erlands, we used A/Netherlands/306/00. This virus contains the LPFDKT
TIM variant of the NP418–426 epitope (designated NPDTI, Table II). The
infectious virus titers of the virus preparations were determined in cell
culture using Madin-Darby canine kidney cells as indicator cells, as de-
scribed previously (23). All peptide analogues of epitope NP418–426 found
in human influenza A viruses were manufactured, HPLC purified, and an-
alyzed by mass spectrometry (Eurogentec, Seraing, Belgium). Influenza A
virus NP sequence information was obtained from the Influenza Sequence
Database (Los Alamos National Laboratories, Los Alamos, NM) (24). Pep-
tides were dissolved in DMSO at 5.0 mg/ml, diluted to 100 M in RPMI
1640 (Invitrogen, Breda, The Netherlands), and stored at 20°C until use.
In vitro stimulation of PBMC with influenza A virus
Stimulation of PBMC with influenza A virus was performed as previously
described (25). The cells were resuspended at 106 cells/ml in RPMI 1640
medium supplemented with 10% FCS, 2 mM glutamine, 100 g/ml strep-
tomycin, and 100 IU/ml penicillin (R10F). Following a 1-h infection at
37°C with Resvir-9, A/Victoria/3/75 or A/Netherlands/306/00 at a multi-
plicity of infection of three, the cells were washed once and resuspended in
RPMI 1640 medium supplemented with 10% human AB serum, 2 mM
glutamine, 100 g/ml streptomycin, 100 IU/ml penicillin, and 20 M
2-ME (R10H) and added to uninfected PBMC at a ratio of 1:1 in a 25-cm2
culture flask. The PBMC were incubated for 2 days before rIL-2 (final
concentration 50 U/ml; Chiron, Amsterdam, The Netherlands) was added.
Subsequently, the cells were incubated for 6 days at 37°C and used as
effector cells in a 51Cr release assay or stained with fluorochrome-labeled
HLA-B*3501-peptide tetrameric complexes (see below).
Generation of NP418–426-specific CD8 T cell clones
CTL clones were generated by limiting dilution assay (8) after in vitro
stimulation of PBMC infected with influenza A virus (Resvir-9) or pulsed
with 10 M of the variant NP418–426 epitopes. After two subsequent
rounds of nonspecific stimulation with 1.0 g/ml PHA (Sigma-Aldrich, St.
Louis, MO), the ability of the cells to recognize the NP418–426 epitope
variant used during the initial stimulation was tested in an ELISPOT assay
(see below). The CTL clones with specificity for the NP418–426 epitope
were PHA stimulated in 75-cm2 culture flasks before cryopreservation at
135°C. The CD8CD3 cell phenotype of the NP418–426-specific clones
was confirmed by flow cytometry, using mAb specific for CD3, CD4, and
CD8 (DAKO, Glostrup, Denmark).
Screening of virus or epitope-specific T cell clones by ELISPOT
assay
Approximately 104 cells of a T cell clone were added to an equal number
of HLA-B*3501-positive BLCL cells that were infected with influenza A
virus, uninfected, or loaded with one of the NP418–426 peptide variants in
150 l of R10F in a 96-well V-bottom plate. Following a 1-min centrif-
ugation at 140  g, the plate was incubated for 2 h at 37°C before the cells
were transferred to a 96-well Silent Screen Plate (Nalge Nunc, Rochester,
NY) coated with anti-human IFN-mAb (Mabtech, Nacka, Sweden). After
4 h at 37°C, the plates were washed and developed according to the man-
ufacturer’s recommendations. T cell clones that produced IFN- in the
presence of peptide-loaded BLCL or virus-infected BLCL cells and failed
to produce IFN- after stimulation with negative control BLCL cells were
selected for further investigation.
Preparation of target cells for 51Cr release assay
BLCL were established as previously described (26) and used as target
cells in 51Cr release assays. Cells of an HLA-B*3501-positive BLCL were
infected with Resvir-9, A/Victoria/3/75, or A/Netherlands/306/00 at a mul-
tiplicity of infection of three in RPMI 1640 medium containing 0.1% BSA,
2 mM glutamine, 100 g/ml streptomycin, and 100 IU/ml penicillin
(R0.1B). After 1 h at 37°C, the cells were washed once in R10F and
cultured in R10F for 16 h at 37°C. To test the ability of CTL clones to
recognize synthetic peptides, 106 cells of a BLCL were loaded with 5 M
of different NP418–426 epitope variants for 16 h at 37°C in R10F. Radio-
actively labeling of peptide-loaded and virus-infected BLCL cells was
done with Na251CrO4 for 1 h at 37°C, after which the cells were washed
three times with R10F and used as target cells in a 51Cr release assay. As
a measure of functional avidity of CTL clones (27), the minimal peptide
concentration was determined for which 50% of the target cells were killed
(epitope concentration (EC50)). 51Cr-labeled HLA-B*3501-positive BLCL
cells were distributed in 96-well V-bottom plates. Next, the cells were
subsequently incubated with 10-fold serial dilutions of peptide analogues
of different NP418–426 epitope variants in R10F for 1 h at 37°C, washed
once in R10F, and used as target cells.
51Cr release assay
51Cr release assays were performed as described previously (25). T cell
clones were added to 5  103 51Cr-labeled target cells at different E:T cell
ratios. Following a 4-h incubation at 37°C, the culture supernatants were
harvested (Skatron Instruments, Sterling, VA) and radioactivity was mea-
sured by gamma counting. The percentage of specific lysis was calculated
with the following formula: ((experimental release spontaneous release)/
(maximum release  spontaneous release)]  100. The data are presented
as the average percentage of specific lysis of at least three wells.
Flow cytometry and tetramer staining
HLA-B*3501 molecules were complexed with four different HLA-
B*3501-restricted NP418–426 epitope variants within the NP of influenza A
Table I. HLA-A and -B serotype and age of blood donors
Donor HLA-A and -B Serotype Age (years)
1 A1,2; B57,35 44
2 A3,-; B27,35 46
3 A1,2; B7,35 41
4 A3,26; B27,35 30
5 A1,2; B8,35 37
6 A1,2; B8,35 48
7 A1,3; B8,35 38
Table II. Variants and virus origin of NP418–426 epitopes
Epitope
Name
Epitope
Sequence Virus Strain
First Year of
Introduction Virus Subtype
NPDTI LPFDKTTIM A/Netherlands/306/00 1977 H1N1
NPDPI LPFDKPTIM — 1957 H2N2/H3N2
NPDSI LPFDKSTIM A/Victoria/3/75 1972 H3N2
NPESV LPFEKSTVM Resvir-9 1980 H3N2
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virus (NPESV, NPDSI, NPDTI, NPDPI) as previously described (20). These
natural variants of the NP418–426 epitope were selected based on the pre-
dominance of these variants since 1957 in H2N2 (NPDPI), since 1968 in
H3N2 viruses (NPESV, NPDSI, NPDPI) and since 1977 in H1N1 viruses
(NPDTI). HLA-B*3501-peptide complexes were enzymatically biotinyl-
ated, fast protein liquid chromatography purified, and tetramerized by ad-
dition of allophycocyanin- or PE-conjugated streptavidin (Sanquin Re-
search at CLB, Amsterdam, The Netherlands). Two- or three-color
fluorescence analysis was performed as described previously (28). Briefly,
CTL clones (105) were stained in PBS supplemented with 2.0% FCS (P2F)
and combinations of two HLA-B*3501-peptide tetrameric complexes with
different NP418–426 epitope variants at nonsaturating concentrations. After
staining for 20 min at 20°C, cells were washed with P2F and at least 104
events were acquired using a FACSCalibur flow cytometer (BD Bio-
sciences, Alphen a/d Rijn, The Netherlands). Tetramer staining of influenza
A virus-stimulated PBMC was performed after 8–10 days of culture. Two
hundred thousand cells were stained in P2F with combinations of two
different HLA class I tetramers for 20 min at 20°C, followed by a 10-min
incubation with anti-CD8 mAb at 20°C. Cells were washed with P2F and
on average 104 CD8 cells were acquired. Data were analyzed using the
software program CellQuest Pro (BD Biosciences). A proportion tetramer-
positive cells in the CD8 cell fraction of 0.4% was considered positive.
Multidimensional scaling (MDS)
An “antigenic map” based on the reactivity of the CTL clones against the
variant peptides was constructed from the EC50 values of the variant
NP418–426 peptides for each CTL clone (29, 30). The map-making tech-
nique is a combination of metric (31) and nonmetric (32) MDS. The dis-
tance between two grids in the map corresponded to a 10-fold dilution of
the peptide, starting at an EC50 value of 0.001 nM (the most parsimonious
choice for these data). The distance between a peptide and a CTL clone or
two peptides is a measure for respectively the avidity between peptides and
a CTL clone or antigenic dissimilarity between variant peptides. The clones
and the peptides are positioned to minimize the sum of the squared errors
between the target distances and the achieved map distances. The average
error between target and achieved distances is 0.37 10-fold dilutions (SD
0.45), indicating a good fit in two dimensions.
Results
Validation of staining of NP418–426-specific CTL with
differentially labeled tetramers
In addition to six previously described CTL clones (Ref. 9 and
Table III), obtained after stimulation with two NP418–426 epitope
variants associated with the H3N2 subtype of influenza A viruses
(NPESV and NPDSI), three additional CTL clones were generated
against the currently circulating NP418–426 epitope variant of
H1N1 viruses (NPDTI). The original stimulation protocol and or-
igin of PBMC is given for each CTL clone (Table III). All CTL
clones exhibited lytic activity against at least one of the viruses
(Table IV). CTL clones D1, C10, 15.9, F10, and G2 lysed target
cells infected with Resvir-9, but not cells infected with A/Victoria/
3/75 or A/Netherlands/306/00. In contrast, CTL clones 2384,
5017, and C4 recognized both the A/Netherlands/306/00- and
A/Victoria/3/75-infected target cells but not the Resvir-9-infected
cells. Finally, clone 3180 recognized all three virus-infected target
cells to a similar extent, demonstrating the ability of this CTL
clone to recognize homo- and heterosubtypic variants of the
NP418–426 epitope present in influenza A viruses of the H3N2 and
H1N1 subtype. The CTL activity of the NP418–426-specific CTL
clones was used for comparison with staining using HLA-B*3501-
peptide tetrameric complexes (tetramers). The dot plots generated
after flow cytometry following incubation with differentially la-
beled tetramers are shown in Fig. 1. CTL clone G2 (Fig. 1) as well
as CTL clones D1, C10, 15.9, and F10 (data not shown) bound to
the NPESV tetramer, but did not react with any of the other tet-
ramers, confirming the failure of these T cell clones to recognize
homo- and heterosubtypic variants of the NP418–426 epitope.
Clone 2384 (Fig. 1) and 5017 (data not shown) reacted with the
tetramers containing the NPDTI and NPDSI peptide, but not with
those containing the NPDPI or the NPESV variant of the epitope.
CTL clone C4 reacted similarly to clone 2384 and 5017, but also
bound the NPDPI tetramer (Fig. 1). Finally, clone 3180 bound all
four tetramers containing different homo- and heterosubtypic vari-
ants of the epitope confirming the cross-reactive nature of this T
cell clone. Overall, the ability of the CTL clones to bind tetramers
with different peptides correlated well with their ability to kill vi-
rus-infected target cells.
Antigenic properties of NP418–426 epitope variants
The antigenic properties of the epitope variants were studied by
measuring the functional avidity of the respective T cell clones as
EC50 value for each of the peptides (Table V). An example of such
an analysis is shown for CTL clone 3180 (Fig. 2). Using the EC50
values, an antigenic map was constructed by MDS. Using this
mathematical procedure, the antigenic dissimilarity of the peptides
and the avidity of NP418–426-specific CTL clones for these pep-
tides is visualized by the relative positioning of the peptides and T
cell clones in a plot (Fig. 3). The glutamic acid (E) to an aspartic
acid (D) substitution at P4 or vice versa reduced functional avidity
Table III. CTL clone definition
CTL
Clone Stimulation
Influenza A Virus
Subtype
Epitope
Name Donor
D1 LPFEKSTVM H3N2/1980 NPESV 5
C10 LPFEKSTVM H3N2/1980 NPESV 5
15.9 Infection with Resvir-9 H3N2/1980 NPESV 6
F10 LPFEKSTVM H3N2/1980 NPESV 7
G2 LPFEKSTVM H3N2/1980 NPESV 7
2384 LPFDKTTIM H1N1 NPDTI 1
5017 LPFDKTTIM H1N1 NPDTI 4
3180 LPFDKTTIM H1N1 NPDTI 5
C4 LPFDKSTIM H3N2/1972 NPDSI 5
Table IV. Virus specificity of NP418–426-specific CTL clones
CTL Clone
% Specific Lysisa
Resvir-9
(NPESV)
A/Victoria/3/75
(NPDSI)
A/Netherlands/306/00
(NPDTI)
D1 72 3 14
C10 73 0 6
15.9 63 12 3
F10 61 1 0
G2 91 14 26
2384 0 58 63
5017 2 60 74
3180 62 42 63
C4 0 53 44
a Average was calculated from two assays. The values represent the specific lysis
minus the background lysis of uninfected target cells. The E:T ratio was 10:1.
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of six CTL clones (15.9, F10, G2, 2384, 5017, and C4), but not of
clone 3180, D1, and C10 (Table V). The large distance in the MDS
plot between peptides containing an E and those containing a D at
P4 exemplified their antigenic dissimilarity. The lysine (K) to ar-
ginine (R) substitution at P5 reduced the functional avidity of CTL
clones 2384, 5017, and 3180. As a result, an R at P5 outplaced
peptide LPFDRTTIM, confirming the importance of a K at this
position for recognition by these NPDTI-specific CTL clones (Fig.
3). CTL clone C4 tolerated both the S3T and the S3P substi-
tutions at P6. CTL clones 2384, 5017, and 3180 all tolerated the
T3S substitution, but the T3P substitution reduced the avidity of
clones 2384 and 5017 more than 10,000-fold and that of clone
3180 300-fold. The S3T substitution at P6 significantly reduced
the functional avidity of four of the NPESV-specific CTL clones
(D1, C10, 15.9, and F10) when the reactivity to the LPFEKSTIM
was compared with that to LPFEKTTIM. CTL clones D1, C10,
15.9, G2, and C4 tolerated a valine (V) to isoleucine (I) substitu-
tion at P8, while the EC50 value for this variant epitope increased
by a factor of 260 in CTL clone F10. In the antigenic map (Fig. 3),
the NPESV-specific T cell clones (D1, C10, 15.9, F10, and G2)
were positioned in close proximity to the LPFEKSTVM peptide
against which they were raised in vitro. Likewise, clones 2384,
5017, and C4 were positioned in proximity of their homologous
peptides, although C4 was situated closer to the heterologous pep-
tide LPFDKTTIM and clones 2384 and 5017 to the heterologous
peptide LPFDKSTIM. Finally, clone 3180 was positioned in the
middle of the plot, close to the H1N1 peptide and the H3N2 pep-
tides from 1972 and 1980, confirming its ability to recognize het-
ero- and homosubtypic variants of the NP418–426 epitope.
Staining of influenza A virus-stimulated PBMC with
HLA-B*3501-peptide tetramers that contain different
NP418–426 variants
The specificity of NP418–426 tetramer staining was confirmed with
well-defined CTL clones and this technology was then used to
evaluate the specificity of NP418–426-specific human polyclonal
CTL responses using PBMC stimulated with influenza A virus.
Following stimulation of PBMC of five HLA-B35 donors with
Resvir-9, a H3N2 virus containing the NPESV epitope, the percent-
age of NPESV-specific cells ranged from 1.1 to 18.5% of the CD8
Table V. Functional avidity (EC50 value) of the CTL clones for the NP418–426 epitope variantsa
Peptide Variants
CTL Clones
H3N2/1980 (NPESV) H1N1 (NPDTI)
H3N2/1972
(NPDSI)
LPF - - - T - Mb D1 C10 15.9 F10 G2 2384 5017 3180 C4
—DKT-I- 5  103 5  103 5  103 5  103 5  103 0.7 0.1 0.08 2c
—DKP-I- 5  103 5  103 5  103 5  103 5  103 104 104 26 0.8
—DKS-I- 18 17 104 5  103 5  103 0.1 0.1 0.5 2
—DKS-V- 0.8 0.8 104 12 5  103 0.1 0.1 11 2
—DRT-I- 104 104 80 5  103 100 5  103 104 1100 5  103
—EKS-I- 0.8 1.0 0.1 8 0.8 104 500 1.1 5  103
—EKS-V- 0.2 0.8 0.1 0.03 0.1 5  103 5  103 0.5 5  103
—EKT-I- 5  103 5  103 10 5  103 8 5  103 5  103 3 5  103
a Absence of lytic activity at a concentration of 5 M peptide is depicted as5 103 nM, while a value of104 means that the EC50 value could not be determined; however,
target cells were lysed at a concentration of 5 M peptide.
b Consensus sequence.
c EC50 value in nanomolar.
FIGURE 1. Binding of HLA-B*3501-peptide tetrameric complexes
containing different NP418–426 epitope variants to NP418–426-specific CTL
clones. The NP418–426-specific CTL clones were incubated with five dif-
ferent combinations of tetramers containing four different variants of the
NP418–426 epitope (NPESV, NPDSI, NPDTI, NPDPI). NPDTI tetramer is PE
labeled, NPDSI and NPDPI tetramers are allophycocyanin labeled, and
NPESV tetramers are available with PE and allophycocyanin-fluorochrome
label. Presented are four CTL clones with different reactivity patterns rep-
resentative of the remaining five clones.
FIGURE 2. Functional avidity of NP418–426-specific CTL clone 3180.
The ability of CTL clone 3180 to lyse target cells pulsed with 10-fold serial
dilutions of eight different variants of the NP418–426 epitope was deter-
mined. The concentration (nanomolar) at which 50% of the target cells
(EC50 value) at an E:T ratio of 10:1 were killed was determined. Each
symbol represents a different NP418–426 epitope variant, including nonpep-
tide pulsed target cells as a negative control (Œ).
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cells (Fig. 4a and data not shown). In the same PBMC cultures, the
percentage of NPDTI-, NPDSI-, and NPDPI-specific cells was also
determined using HLA-B*3501-peptide tetrameric complexes
containing the respective peptides. In the in vitro expanded PBMC
of donor 1 small numbers of NPDTI and NPESV double-reactive
CD8 cells were observed (0.4%), demonstrating the presence of
heterosubtypic reactive CD8 cells (Fig. 4a). In the PBMC of the
remaining four donors, no NPDTI-specific cells were detected after
stimulation with Resvir-9. The ability to recognize homosubtypic
variants of the NP418–426 epitope following stimulation with a
virus containing the NPESV variant peptide (Resvir-9) was variable
between donors. In donors 1 and 2 a fraction of the NPESV-specific
cells also bound to NPDSI tetramers (Fig. 4a), while in donors 3–5
the NPESV-specific cells did not bind to NPDSI tetramers (Fig. 4a
and data not shown). Finally, in vitro expanded NPESV-specific
CD8 cells did not bind to the NPDPI tetramer (Fig. 4a). Similar
experiments were performed with PBMC following stimulation
with influenza viruses A/Victoria/3/75 (H3N2, NPDSI) or A/Neth-
erlands/306/00 (H1N1, NPDTI). Of each of the five donors tested,
0.4–4.5% of the CD8 cells that were expanded after stimulation
with influenza virus A/Victoria/3/75 bound to the homologous NP-
DSI tetramers. In some donors, a large fraction of the NPDSI-spe-
cific cells also bound to the NPDTI tetramers (donors 1, 3, and 4,
Fig. 4b and data not shown), indicating a high degree of cross-
reactivity between these epitopes. The NPDSI-specific cells from
donor 2 however, cross-reacted with the NPESV tetramer and not
with the NPDTI tetramer, confirming the existence of homosub-
typic cross-reactive CTL in this donor. Upon stimulation with in-
fluenza virus A/Netherlands/306/00, NPDTI-specific CD8 cells
were detected in some PBMC cultures (range, 0.0–6.2%, Fig. 4c).
Most of the NPDTI-specific CD8 cells also bound the NPDSI tet-
ramers (donors 1, 3, and 4, Fig. 4c and data not shown). In addi-
tion, a portion of the NPDTI-specific cells from donor 1 cross-
reacted with NPESV tetramers (Fig. 4c), confirming the existence
of these cells following stimulation with Resvir-9 virus. Finally,
only in donor 3 some NPDTI-specific cells in the PBMC cultures
stimulated with A/Netherlands/306/00 also bound to the NPDPI
tetramers (Fig. 4c). Thus, tetramer staining provided evidence for
the existence of CTL cross-reactive with current H3N2 (NPESV)
and H1N1 (NPDTI) viruses in one donor, whereas in the other four
donors only influenza A virus subtype-specific cells were demon-
strated or cells cross-reactive with previous H3N2 (NPDSI) and
current H1N1 (NPDTI) viruses.
Influenza A virus-specific Ab titers
To correlate the NP418–426-specific CTL response in the PBMC of
donors to the history of influenza A virus infections, serum HAI
titers specific for A/H1N1 and A/H3N2 viruses were determined.
Serum Abs were detected in donor 1 against the 1978 vaccine
strain (H1N1), which cross-reacted with later vaccine strains, and
the 1991 vaccine strain. Abs specific for H3N2 viruses were ob-
served against A/Hong Kong/1/68 (NPDPI) and the 1995 vaccine
strain (NPESV). These findings indicate that donor 1 was exposed
to influenza A viruses of the H1N1 subtype around 1978 and 1991
and to the H3N2 viruses around 1968 and 1995 (Fig. 4d). In donor
2, Abs specific for 1968, 1977, and 1995 vaccine strains of the
H3N2 subtype were readily detected (Fig. 4d). These findings sug-
gest that this donor has experienced multiple exposures to influ-
enza A viruses of the H3N2 subtype but not to those of the H1N1
subtype. Donor 3 had serum Abs against the 1968 and 1995 strain
of the H3N2 subtype (Fig. 4d) and low levels of Abs against the
1978 and 1983 strains of the H1N1 subtype. Donor 4 was found to
have serum Abs to viruses of the A/H3N2 (1977, 1979, 1982,
1987, and 1995) and the A/H1N1 subtype (1978, 1983, and 1996),
whereas in donor 5 solely Abs against viruses of the H3N2 subtype
from 1977, 1979, 1995, and 1998 were detected (data not shown).
Discussion
In the present study, the recognition of natural variants of an HLA-
B*3501-restricted CTL epitope within the NP of influenza A vi-
ruses by human clonal and polyclonal CTL populations was in-
vestigated. Using classical 51Cr release assays and direct
visualization of specific T cells with tetramers, CTL were identi-
fied that were cross-reactive with homo- and heterosubtypic vari-
ants of the epitope. The use of CTL clones specific for the respec-
tive epitope variants allowed the identification of residues involved
in TCR recognition. Based on the finding that cross-reactive CTL
were found at low frequencies in PBMC stimulated with influenza
virus, we hypothesize that in response to influenza virus infections,
HLA-B*3501-positive individuals develop a CTL response against
the homologous epitope variant of which a small proportion may
be cross-reactive with other variants. These cross-reactive cells
may then be further expanded upon a subsequent infection with
viruses carrying a heterologous variant epitope. It was assumed
that the study subjects were infected in the past with a homoge-
neous virus population with regard to the epitope NP418–426, based
on epidemiological data on the circulation of these variants (24).
The results obtained in 51Cr release assays with virus-infected
target cells and direct visualization with labeled tetramers corre-
lated well, confirming the specificity of these procedures and the
antigenic dissimilarity of the epitopes. Using serial dilutions of the
peptides, the avidity of the CTL clones for the peptides was de-
termined in 51Cr release assays and the effect of the amino acid
substitutions was assessed. In vitro three T cell clones were estab-
lished after stimulation with peptide NPDTI (5017, 2384, and 3180)
and one after stimulation with NPDSI (C4). Although these clones
had high avidity for these peptides, it is not clear which variant of
the epitope had primed these CTL in vivo. As can be judged from
FIGURE 3. An antigenic map visualizing functional avidity between
the variant NP418–426 peptides and the CTL clones. The functional avidity
between the peptides and CTL clones was calculated as EC50 values (Table
V). The CTL clones are depicted by squares while circles represent
the variant peptides. The large circles contain the CTL clones and the
NP418–426 epitope variant used for in vitro stimulation of these clones. The
distance between two grids corresponds to a 10-fold dilution in EC50 value.
For example, the EC50 value for clone 15.9 with peptide LPFEKSTIM is
0.1 nM; this is two 10-fold dilutions from the assumed baseline titer of
0.001 nM, thus the “target” distance from clone 15.9 to peptide LPFEK
STIM when constructing the map was 2 U.
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the EC50 values (Table V) and the MDS plot (Fig. 3), some clones
exhibited the highest avidity for a heterologous peptide. For ex-
ample, clone C4 may have been directed to NPDPI and clone 2384
to NPDSI. In contrast, T cell clones raised in vitro to peptide NPESV
all showed the highest avidity to this peptide, suggesting that in-
deed it was the homologous peptide responsible for the activation
of these cells in vivo. MDS proved to be a useful aide in the
interpretation of EC50 values and allowed the direct visualization
of recognition patterns of the respective CTL clones and the anti-
genic differences between epitopes.
The NP418–426 epitope was found to vary in influenza viruses
isolated during the past 70 years at positions 4, 5, 6, and 8 of the
9-mer epitope. All peptides retained the anchor residues at posi-
tions 2 and 9, indicating that they bind to HLA-B*3501 with equal
affinity, as has been demonstrated previously in an HLA peptide-
binding assay (9). Substitutions at P4 and P5 were found to have
the largest effect on recognition by specific T cells as can be judged
from the EC50 values and therefore the antigenic distance in the
MDS plot. The D421E substitution in 1980 allowed the virus to
escape from NPDSI-specific CTL (9). These findings coincide with
data obtained with dengue virus-specific CTL, confirming the im-
portance of position 4 for the recognition of an HLA-B*3501-
restricted epitope (33). Although a mutation at P4 had a major
impact on TCR recognition, CTL do exist (3180) that recognize
peptides containing either an E or a D at position 4. These CTL
may have been selected for by repeated infections with different
influenza A viruses containing different variants of the epitope.
The K422R substitution also had a dramatic effect on the recogni-
tion of the epitope. However the R at amino acid position 422 on
the NP is rare and has only been found in influenza A viruses
isolated in 1933 and 1934 and in several human isolates of avian
origin. Substitutions at P6 and P8 had relatively little impact on
TCR recognition, although for most NPESV-specific T cell clones
the T3S substitution at P6 reduced the TCR avidity for the
FIGURE 4. Tetramer-staining of polyclonal NP418–426-specific CTL response in PBMC stimulated with influenza A virus. PBMC of donors 1–5 were
stimulated in vitro with Resvir-9 (NPESV), A/Victoria/3/75 (NPDSI), or A/Netherlands/306/00 (NPDTI) for 8–10 days before tetramer staining with com-
binations of two NP418–426 epitope variant-containing tetramers conjugated to two different fluorochromes. Depicted are donors 1, 2, and 3, respectively,
stained with NPESV tetramers (vertical) and NPDTI, NPDSI, or NPDPI tetramers after stimulation with Resvir-9 (A) or NPDSI tetramers (vertical) and NPDTI
or NPESV tetramers following stimulation with A/Victoria/3/75 (B) or NPDTI tetramers (vertical) and NPESV, NPDSI or NPDPI tetramers following stimulation
with A/Netherlands/306/00 (C). Staining profiles of donors 4 and 5 were not shown, since they resembled those of donor 3 (donor 4) or had low to
undetectable levels of tetramer-positive cells. The percentages indicate the percentage of tetramer-positive cells in 104 CD8 cells. D, Influenza A
virus-specific HAI titers in plasma of HLA-B35 blood donor HAI assays were performed on plasma obtained from donors 1–5 using 6 different H1N1
vaccine strains (E) and 11 different H3N2 vaccine strains (F) used since 1968. The HAI titers specific for each vaccine strain are depicted for donors 1–3
against the years in which the vaccine strains were isolated.
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epitope. In contrast to NP418–426-specific CTL, CTL specific for
an HLA-B*3501-restricted epitope of dengue virus (NS500–508)
tolerated an amino acid substitution at position 8 poorly (33).
Upon stimulation of PBMC with different influenza A viruses,
various recognition patterns were observed that correlated partially
with the history of infections of the respective donors (see below).
In three donors (donors 1, 3, and 4), CTL expanded after stimu-
lation with influenza virus A/Netherlands/306/00 (of the H1N1
subtype containing NPDTI) were cross-reactive with the NPDSI
variant present in influenza viruses of the H3N2 subtype, circulat-
ing between 1972 and 1980 and vice versa. Thus, also stimulation
with A/Victoria/3/75 (H3N2) led to the expansion of NPDSI-spe-
cific cells cross-reactive with NPDTI. This finding resembles the
cross-reactivity observed with CTL specific for epitopes in HIV-1,
dengue virus, and SIV (33–35). HIV-1-specific CTL could recog-
nize variants of epitopes present in different clades of this virus.
An important difference between influenza virus and HIV-1 infec-
tions is that individuals usually are not infected with HIV from
different clades whereas for influenza, repeated infections with
variant viruses of distinct or the same subtype is very common. For
that reason, repeated infections with variant viruses may select for
cross-reactive CTL from the pool of NP418–426-specific CTL in-
duced during the primary infection. To correlate the presence of
cross-reactive CTL with the history of influenza A virus infections
of the respective donors, serology was performed. Because of the
relative insensitivity of the HAI assay and waning Ab titers over
time, failure to detect serum Abs against a certain virus may not be
conclusive regarding the lack of exposure to this virus in the past.
However, a positive result in this assay was considered indicative
for a history of infection. Donor 1 was infected with an influenza
A virus of the H1N1 subtype and subsequently with an H3N2
virus. This is in agreement with the observation in this donor of
NPDTI- and NPESV-specific cells. A small proportion of these cells
cross-reacted with NPESV and NPDTI. The strong staining with the
NPESV tetramers (NPESVhigh) and the relatively weak staining with
the NPDTI tetramer (NPDTIlow) of these double-reactive CTL de-
tectable after stimulation of PBMC with Resvir-9 and A/Nether-
lands/306/00 suggests that these NPESVhighNPDTIlow CTL have a
stronger avidity for the NPESV variant of the epitope. However,
since the tetramers were used at nonsaturating concentrations it is
impossible to draw firm conclusions regarding the avidity of the
CD8 cells for the respective tetramers. Donors 2 and 5 were
found to be exposed to viruses of the H3N2 subtype circulating in
1977 and 1995 and not to H1N1 viruses. As a result, NPESV mono-
specific CTL were found in both donors and not T cells reactive
with the NPDTI (H1N1) variant of the epitope. In addition, homo-
subtypic cross-reactive CTL were found in donor 2. In donor 4, the
serology correlated with the presence of NPESV- and NPDTI-spe-
cific cells, although cross-reactive cells were not observed in this
donor. A similar reaction pattern was observed in donor 3, al-
though H1N1-specific Ab titers were very low. The absence of
heterosubtypic cross-reactive CTL may be explained by the long
period between infection with an H1N1 virus and an H3N2 virus.
Thus, in two of five donors tested, there was evidence for
the existence of T cells cross-reactive with homo- and heterosub-
typic variants of the NP418–426 epitope. The heterogeneity in the
NP418–426-specific responses in these donors of similar age can be
the result of differences in history of infection as well as many
other factors influencing the CTL response in these donors.
In mice it has been demonstrated ex vivo (17) and in vitro (18)
that consecutive infections with influenza viruses containing dif-
ferent variants of the same epitope (NP366–374) resulted in the ex-
pansion of CTL able to recognize both variants of the epitope,
whereas infection with the same virus resulted in the induction of
monospecific cells. This expansion of cross-reactive CTL may
even take place after consecutive infections with unrelated viruses
as has also been observed in mice (36, 37). We hypothesize that
also in humans cross-reactive CTL can be selected for against
variable epitopes by multiple infections with influenza viruses car-
rying variant epitopes (apart from true cross-reactive responses
against conserved epitopes).
The percentage of heterosubtypic cross-reactive T cells specific
for the NP418–426 epitope is relatively small in the subjects com-
pared with those observed in vivo in mice. In some of the donors,
there was no evidence for exposure to both subtypes, explaining
the absence of cross-reactive CTL. The timing of the infections
may be crucial as the frequency of cross-reactive CTL in the pool
of memory cells may have declined to undetectable levels, unable
to dominate the response to the variant epitope.
We conclude that upon influenza virus infections a small pro-
portion of the NP418–426-specific CTL can cross-react with vari-
ants of the epitope. Apparently the flexibility of the TCR of this
subset of CTL allows the recognition of naturally occurring vari-
ants of the epitope that may be escape mutants selected for by
CTL-mediated immune pressure. This subset of cross-reactive
CTL may increase after repeated infections with heterologous vi-
ruses and may contribute to protective immunity against arising
mutant viruses.
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